Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm.

Brachytherapy Radiotherapy Surgery Uveal melanoma

Journal

Radiation oncology journal
ISSN: 2234-1900
Titre abrégé: Radiat Oncol J
Pays: Korea (South)
ID NLM: 101577577

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 27 05 2020
accepted: 19 06 2020
entrez: 4 10 2020
pubmed: 5 10 2020
medline: 5 10 2020
Statut: ppublish

Résumé

Uveal melanoma (UM), the most frequently occurring non-cutaneous melanoma and most common primary intraocular malignancy in adults, arises from the melanocytes of the choroid in approximately 95% of cases. Prompt diagnosis and treatment is vital as primary tumor size is one of the key factors associated with survival. Despite recent advances in management, more than half of the patients develop metastatic disease which portends poor survival. Currently, treatment options for UM include local resection, enucleation, plaque brachytherapy, and/or particle beam radiotherapy (RT). Enucleation was initially the standard of care in the management of UM, but a shift towards eye-preserving therapeutic choices such as RT and local resection has been noted in recent decades. Plaque brachytherapy, a form of localized RT, is the most popular option and is now the preferred treatment modality for UM. In this review we discuss the etiopathogenesis, clinical presentation and diagnosis of UM and place a special emphasis on therapeutic options. Furthermore, we review the current literature on UM management and propose a functional treatment algorithm for non-metastatic disease.

Identifiants

pubmed: 33012143
pii: roj.2020.00318
doi: 10.3857/roj.2020.00318
pmc: PMC7533402
doi:

Types de publication

Journal Article

Langues

eng

Pagination

162-169

Références

Cancer. 2005 Mar 1;103(5):1000-7
pubmed: 15651058
Br J Ophthalmol. 2010 Apr;94(4):460-6
pubmed: 19965818
Pract Radiat Oncol. 2014 Jul-Aug;4(4):e189-94
pubmed: 25012839
PLoS One. 2015 Mar 12;10(3):e0116371
pubmed: 25764247
Phys Med Biol. 2007 Oct 7;52(19):5957-71
pubmed: 17881812
Int J Cancer. 2014 Mar 1;134(5):1207-13
pubmed: 23934701
Am J Ophthalmol. 2016 May;165:78-87
pubmed: 26940166
Strahlenther Onkol. 2005 Dec;181(12):783-8
pubmed: 16362788
Ophthalmology. 2014 Jan;121(1):269-275
pubmed: 24139123
JAMA Ophthalmol. 2015 Jul;133(7):792-6
pubmed: 25905597
Br J Ophthalmol. 1978 Jun;62(6):420-5
pubmed: 352389
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):867-80
pubmed: 12605964
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Arch Ophthalmol. 1997 Dec;115(12):1537-44
pubmed: 9400787
Am J Ophthalmol. 2011 Apr;151(4):579-585.e1
pubmed: 21238949
Eye (Lond). 2015 Sep;29(9):1194-8
pubmed: 26160531
Eye (Lond). 2016 Jun;30(6):833-42
pubmed: 27034202
Photochem Photobiol. 2014 Jan;90(1):15-21
pubmed: 23981010
Br J Ophthalmol. 2016 Apr;100(4):463-7
pubmed: 26224096
Br J Ophthalmol. 2004 Jul;88(7):962-7
pubmed: 15205248
Ophthalmology. 2002 Oct;109(10):1855-61
pubmed: 12359606
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4719-24
pubmed: 26207308
Arch Ophthalmol. 2006 Feb;124(2):226-38
pubmed: 16476893
Br J Ophthalmol. 2015 Dec;99(12):1644-9
pubmed: 25979763
Brachytherapy. 2016 Mar-Apr;15(2):216-23
pubmed: 26846381
Int Ophthalmol Clin. 2006 Winter;46(1):95-107
pubmed: 16365558
Eye (Lond). 2012 Sep;26(9):1157-72
pubmed: 22744385
Oncotarget. 2016 Jan 26;7(4):4624-31
pubmed: 26683228
Ophthalmology. 2009 Feb;116(2):340-8
pubmed: 19091418
Ophthalmology. 2015 Mar;122(3):600-9
pubmed: 25439431
Arch Ophthalmol. 2006 Jan;124(1):54-60
pubmed: 16401785
Radiother Oncol. 2010 Jun;95(3):332-8
pubmed: 20416963
Oncologist. 2016 Jul;21(7):848-54
pubmed: 27286787
Br J Ophthalmol. 2017 Jun;101(6):747-751
pubmed: 27574179
Graefes Arch Clin Exp Ophthalmol. 2007 Apr;245(4):522-33
pubmed: 17111148
Arch Ophthalmol. 2002 Jul;120(7):933-40
pubmed: 12096964
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3335-3342
pubmed: 28672400
PLoS One. 2015 Sep 14;10(9):e0138002
pubmed: 26368812
Curr Opin Ophthalmol. 2018 May;29(3):191-198
pubmed: 29538180
Ophthalmology. 2003 Nov;110(11):2235-44
pubmed: 14597535
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):376-83
pubmed: 25841624
Ophthalmology. 2009 Apr;116(4):790-6, 796.e1
pubmed: 19243829
Ophthalmology. 2012 Aug;119(8):1582-9
pubmed: 22503229
Genes Dev. 2017 Apr 15;31(8):724-743
pubmed: 28512236
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4666-73
pubmed: 17065472
Int Ophthalmol Clin. 2006 Winter;46(1):81-93
pubmed: 16365557
Arch Ophthalmol. 2009 Aug;127(8):981-7
pubmed: 19667334
Ocul Oncol Pathol. 2017 Sep;3(3):193-198
pubmed: 29071269
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):98-103
pubmed: 19910136
Br J Ophthalmol. 2014 Jan;98(1):82-5
pubmed: 24169650

Auteurs

Mutlay Sayan (M)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Swati Mamidanna (S)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Damla Oncel (D)

Department of Biochemistry, University of California, Los Angeles, CA, USA.

Imraan Jan (I)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Irina Vergalasova (I)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Joseph Weiner (J)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Nisha Ohri (N)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Banu Acikalin (B)

Department of Ophthalmology, Istanbul Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.

Anupama Chundury (A)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Classifications MeSH